CompletedPhase 3

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

Germany130 participantsStarted 2005-05

Plain-language summary

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

Who can participate

Age range6 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Bronchial asthma * Requirements for inhaled corticosteroid * Positive skin prick test to house dust mite * Positive radioallergosorbent test (RAST) to house dust mite * Positive provocation test result to house dust mite Exclusion Criteria: * Serious chronic diseases * Other perennial allergies

What they're measuring

Inhalative dose of fluticasone propionate

Timeframe: After 2 years

Trial details

NCT IDNCT00263640

SponsorAllergopharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-04

View on ClinicalTrials.gov More Respiratory Hypersensitivity trials